NCT05867212View on ClinicalTrials.gov

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

May 13, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
HIV Infections
Interventions
DRUG

Cabotegravir Injection [Apretude]

People who want to get the long acting injectable will have the option in participating in surveys after their visit and have their electronic health records reviewed.

Trial Locations (2)

98104

Kelley-Ross Pharmacy at the Polyclinic, Seattle

98122

Kelley-Ross Capitol Hill Pharmacy, Seattle

All Listed Sponsors
lead

Kelley-Ross & Associates, Inc.

OTHER

NCT05867212 - Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting. | Biotech Hunter | Biotech Hunter